Loading IPCA Laboratories…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 2,788 | 2,388 | 2,393 | 2,557 | 2,309 |
| Operating profit | 559 | 377 | 426 | 442 | 316 |
| Operating margin | 20.0% | 15.8% | 17.8% | 17.3% | 13.7% |
| Net profit | 402 | 299 | 326 | 283 | 233 |
| Net margin | 14.4% | 12.5% | 13.6% | 11.1% | 10.1% |
| EPS (₹) | 15.84 | 11.79 | 12.86 | 11.14 | 9.19 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 9,563 | 8,855 | 7,622 | 6,207 |
| Operating profit | 1,630 | 1,356 | 934 | 705 |
| Operating margin | 17.0% | 15.3% | 12.3% | 11.4% |
| Net profit | 1,141 | 738 | 547 | 471 |
| Net margin | 11.9% | 8.3% | 7.2% | 7.6% |
| EPS (₹) | 44.98 | 29.08 | 21.57 | 18.58 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 12,370 | 11,761 | 11,101 | 8,626 |
| Total liabilities | 2,846 | 3,372 | 3,374 | 2,711 |
| Shareholders’ equity | 8,064 | 6,948 | 6,332 | 5,842 |
| Total debt | 809 | 1,363 | 1,438 | 1,481 |
| Cash & equivalents | 437 | 167 | 209 | 1,258 |
| Debt / equity | 0.10 | 0.20 | 0.23 | 0.25 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 1,142 | 1,321 | 945 | 806 |
| Capital expenditure | -656 | -776 | -411 | -494 |
| Free cash flow | 486 | 546 | 533 | 311 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 14.2% | 10.6% | 8.6% | 8.1% |
| Return on assets | 9.2% | 6.3% | 4.9% | 5.5% |
| Net margin | 11.9% | 8.3% | 7.2% | 7.6% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for IPCALAB. Finnhub coverage is limited for some India-listed stocks.